drugset / Trial / NCT07532577

Intranasal Insulin to Prevent Intensive Care Unit Delirium

NCT07532577

Phase 2/3 Not yet recruiting 30 enrolled Radboud University Medical Center
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study aims to assess the feasibility, tolerability, and exploratory efficacy of intranasal insulin to prevent delirium in ICU patients aged ≥65 years after complex elective cardiac surgery with cardiopulmonary bypass

Timeline

Start
2026-04-15
Primary completion
2026-07-15
Completion
2026-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 20 iu Intranasal

Indications